Our flow cytometry data revealed that combination treatment with anti-CD47 and anti-PD-L1 increased the levels of tumor PD-1+CD8+ T cells infiltrate and decreased the tumor burden in the MPC-83 but not in the Panc02 syngeneic mouse model. This evidence concerns the gene CD47 and neoplasm.